iRhythm Technologies (IRTC) Stock Forecast & Price Target

iRhythm Holdings Inc. demonstrated a strong financial performance with a gross margin of 71.1%, an increase of 230 basis points year-over-year, which surpassed consensus expectations. The company reiterated its revenue outlook for 2025 in the range of $870-$880 million, reflecting a year-over-year growth rate of 16-18%, supported by consistent 20%+ revenue growth for five consecutive quarters. Additionally, factors such as higher ambulatory cardiac testing volume, robust Zio AT growth, and accelerated international expansion underpin a positive outlook for the company's profitability and operational leverage in the near term.

iRhythm Holdings Inc. faces a negative outlook primarily due to projected growth slowing to the low-teens, coupled with challenges in improving profitability amid stagnant pricing expected in 2026. Key risks include adverse developments in commercial reimbursement rates, increased competition in the cardiac monitoring market, and the potential underperformance of important product launches such as ZioAT, which could diminish market traction. Additionally, concerns over poor sales execution, disruptions within the sales force, and the possibility of an additional equity offering compound the negative sentiment surrounding the company's financial stability.